Key facts
- Notable investors include Whiz Partners.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Ascella Bio Japan
- ·The full record, as it builds
Funding rounds
No funding rounds for Ascella Bio Japan are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ascella Bio Japan
Manufacture and developer of pharmaceutical products intended to offer the option for infectious disease testing. The company offers vitro diagnostics, medical devices, testing equipment and other related products, enabling its clients with simple, rapid testing with PCR-level sensitivity and specificity at an affordable price.
- Sector
- Healthcare
- HQ
- Minato-ku, Japan
- Founded
- 2024
- Website
- ascella-bio.jp/
- Ownership
- Privately Held (backing)
Ascella Bio Japan doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ascella Bio Japan shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ascella Bio Japan in its N-PORT filings yet. We sweep new filings monthly.